Jul 13, 2021 / 04:30PM GMT
Michael Higgins - Ladenburg Thalmann & Co. Inc. - Analyst
Welcome to the Ladenburg Thalmann virtual healthcare conference. My name is Michael Higgins, managing director, senior biotech analyst here. Proud to cover Catabasis; ticker CATB. Launched coverage earlier this year. Happy to have their presentation at our conference. This young company became public as Catabasis earlier this year. And the CEO to present, Jill Milne. Jill, I'll have you take it away. Thank you for joining us.
Jill Milne - Catabasis Pharmaceuticals, Inc. - Co-Founder & Chief Executive Officer
Great. Thank you, Michael. Happy to be here. During my presentation today, I will make statements related to our business based on current and future expectations that might be considered forward-looking statements. And with that, I will get started.
Today I am here to share what we at Catabasis see as a really exciting opportunity to develop what could be the most patient-friendly treatment option for hereditary angioedema patients. This opportunity is in a rare disease with well
Catabasis Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers